Fusion Pharmaceuticals Inc.
FUSNDelisted Jun 5, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001805890
Fusion Pharmaceuticals Inc. was delisted on Jun 5, 2024; its insiders filed their last Form 4 on Jun 4, 2024; 114 institutions reported holding it in 13F filings for Q1 2024, worth $1.47B in total; Duquesne Family Office was the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding Fusion Pharmaceuticals Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 41 | 1 | 41 | +1 |
| Shares | 50.3M | 43.4K | 49.9M | −314.3K (−0.6%) |
| Value | $235.1M | $203.1K | $129.8M | −$105.0M (−44.7%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Fusion Pharmaceuticals Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 78,035 | $202.9K | 0.00% |
| NEOS Investment Management LLC | 17,493 | $45.5K | 0.01% |
| National Bank of Canada | 500 | $1.19K | 0.00% |
| Tower Research Capital LLC (TRC) | 139 | $361 | 0.00% |
Sold out (3)
Institutions that held Fusion Pharmaceuticals Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Two Sigma Investments, LP | 31,154 | $145.5K |
| Schonfeld Strategic Advisors LLC | 14,800 | $69.1K |
| Advisor Group Holdings, Inc. | 30 | $140 |
Not filed for Q3 2023 yet (1)
Institutions that held Fusion Pharmaceuticals Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 43,394 | $203.1K |